Looking to publish in Infectious Diseases And Therapy? Livewrite integrates seamlessly with Word to help you write, edit, and format faster.
Try Livewrite NowInfectious Diseases and Therapy is an international, open access, peer-reviewed, rapid publication journal dedicated to high-quality clinical, observational, real-world, and health outcomes research on infectious disease therapies and interventions, including vaccines and devices. It also welcomes research on diagnostics, pharmacoeconomics, public health, epidemiology, quality of life, patient care, management, and education, and publishes original research, reviews, case reports, trial protocols, short communications, commentaries, editorials, and letters.
Looking to publish in Infectious Diseases And Therapy? Livewrite integrates seamlessly with Word to help you write, edit, and format faster.
Try Livewrite NowSubmission Instructions
Infectious Diseases And Therapy accepts the following article types. Click on an article type to view submission instructions.
Original Article
Review Article
Brief Report
Editorial
Letter to the Editor
Guideline
Recent Publications
HBV Serological Profiles and Vaccination Status in People with HIV in the Transition to a Tenofovir-Sparing Era: Insights from a Large HIV Cohort
Alberto Foncillas, Lorena De La Mora, Leire Berrocal, Elisa de Lazzari, Júlia Calvo, Abiu Sempere, Ivan Chivite, Alexy Inciarte, Maria Martínez-Rebollar, Berta Torres, Ana González-Cordón, Jose Luís Blanco, José. M. Miró, Esteban Martínez, Montserrat Laguno, Josep Mallolas, Juan Ambrosioni
Outcomes and Adverse Events Among Patients with Vancomycin-Resistant Enterococcal Bloodstream Infection Treated with Daptomycin Doses Greater than 12 mg/kg
Luo-Wei Lin, Yu-Chung Chuang, Jia-Ling Yang, Chi-Ying Lin, Sung-Hsi Huang, Jann-Tay Wang, Yee-Chun Chen, Shan-Chwen Chang
Ceftaroline for Methicillin-Resistant Staphylococcus aureus Endovascular Infection
Reese A. Cosimi, Kelsey Peña, John L. Lock, Todd Riccobene, Bhavik Nana, George Sakoulas
Ventilator-Associated Pneumonia Due to ESBL-Producing Escherichia coli Successfully Treated with Cefepime/Enmetazobactam: A European Case Report
Bruno Viaggi, Tommaso Giani, Emanuele Palomba, Andrea Gori, Alberto Farese, Gian Maria Rossolini, Marta Colaneri
Efficacy and Safety of Switching to Dolutegravir/Lamivudine in Virologically Suppressed HIV-1 Infected Adults with TDF-Related Renal or Bone Toxicity
Zhenyan Wang, Li Liu, Jun Chen, Jiangrong Wang, Yinzhong Shen, Tangkai Qi, Yang Tang, Wei Song, Jianjun Sun, Shuibao Xu, Junyang Yang, Youming Chen, Yueming Shao, Renfang Zhang
Frequently asked questions
How long does it take to publish?
2-week peer review; 3-4 weeks from acceptance to online publication; submission to first decision median is 1 day.
Reformat to Infectious Diseases And Therapy using Livewrite PremiumIs a cover letter required?
A cover letter is required to highlight publication deadlines, trial registration details, open access choice for Advances in Therapy, and any relevant submission information.
Reformat to Infectious Diseases And Therapy using Livewrite PremiumWhat are the publication costs?
Mandatory Rapid Service Fee of €5950/$7675/£5120 upon acceptance; open access publication costs included.
Reformat to Infectious Diseases And Therapy using Livewrite Premium